CCA Industries, Inc. Reports Financial Results for Year Ended November 30, 2023
CCA Industries, Inc. Reports Financial Results for Year Ended November 30, 2023
PR Newswire
FORT WASHINGTON, Pa., Feb. 28, 2024
FORT WASHINGTON, Pa., Feb. 28, 2024 /PRNewswire/ -- CCA Industries, Inc. (OTC: "CAWW"), announced today its results for the year ended November 30, 2023. The results can be found on the chart below.
Net loss was $422,866 for the year ended November 30, 2023, as compared to a net loss of $54,017 for the year ended November 30, 2022. Christopher Dominello, Chief Executive Officer commented "Our Company is now well positioned for growth and profitability in 2024. We had several non-cash adjustments to our year-end results totaling $1,290,542 including the write-down of the Solar Sense trademark by $543,990, which we anticipate selling in fiscal 2024. We also wrote down the manufacturing overhead by $393,388 to reflect current inventory value. All of this was done to make that we were prepared for growth in 2024." Dominello also commented, "We expect that Neutein, our brain health supplement, will begin shipping into retail in the second quarter of fiscal 2024. Our Amazon business, and other sites, continue to grow, with sales of nearly $6 million in fiscal 2023, an increase of 36% over the prior year. The Company installed new accounting software that gives management better visibility to our costs and financial results. We also enter 2024 with a stronger Balance Sheet than in previous years. The Company has been going through a series of years with losses, but we believe the shareholders will finally see the results of our turnaround efforts." Audited Financial Statements for the year ended November 30, 2023 and the Annual Disclosure Statement filed with the OTC, may be found on the OTC marketplace web site: https://www.otcmarkets.com
CCA Industries, Inc. manufactures and markets health and beauty aids, each under its individual brand name. The products include, principally, "Plus White" toothpastes and teeth whiteners, "Nutra Nail" nail care treatments, "Porcelana" skin care products, "Scar Zone" scar treatment products, "Sudden Change" anti-aging skin care products, brands, "Hair Off" depilatory products, "Solar Sense" sun care products and "Neutein" brain health supplements.
Statements contained in the news release that are not historical facts are forward looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are subject to risks and uncertainties, which would cause actual results to differ materially, from estimated results. No assurance can be given that the results in any forward-looking statement will be achieved and actual results could be affected by one or more factors, which could cause them to differ materially. For these statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act.
CCA INDUSTRIES, INC. | |||
Year Ended | |||
November 30, 2023 | November 30, 2022 | ||
Revenues | $ 10,486,620 | $ 12,837,910 | |
Net Income | $ (422,866) | $ (54,017) | |
Earnings Per Share: | |||
Basic | $ (0.06) | $ (0.01) | |
Diluted | $ (0.06) | $ (0.01) | |
Weighted Average Common Shares Outstanding: | |||
Basic | 7,561,684 | 7,561,684 | |
Diluted | 7,561,684 | 7,561,684 | |
EBITDA * | $ (259,140) | $ 42,209 | |
* Earnings before interest, taxes, depreciation and amortization | |||
Reconciliation of Net Income to EBITDA: | |||
Net Income | $ (422,866) | $ (54,017) | |
Provision for income taxes | (35,976) | 9,169 | |
Interest expense | 194,497 | 76,577 | |
Depreciation and Amortization | 5,204 | 10,480 | |
EBITDA | $ (259,140) | $ 42,209 | |
View original content:https://www.prnewswire.com/news-releases/cca-industries-inc-reports-financial-results-for-year-ended-november-30-2023-302074927.html
SOURCE CCA Industries, Inc.
-
5 Undervalued Stocks to Buy to Play a Little Defense
-
Markets Brief: AI Leaders Excel In Earnings Season So Far
-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
After Earnings, Is Tesla Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is GE Aerospace Stock a Buy, a Sell, or Fairly Valued?
-
3 Good Stocks to Buy with Your Tax Refund in 2024 (Or with Any Extra Money)
-
SoFi Earnings: Revenue Growth Slows on Lower Loan Growth and Higher Credit Costs
-
Tesla: Full Self-Driving Approval In China Supports Our View for Deliveries Growth In 2024
-
Philips Earnings: Firm Reaches $1.1 Billion Settlement Agreement
-
AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure
-
Exxon Earnings: Ignore Earnings Shortfall as Long-Term Growth and Improvement on Track